Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Date:

November 14, 2024

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and former presidential hopeful Robert F. Kennedy Jr. as his pick to lead the U.S. Department of Health and Human Services.

Source link

BREAKING: Trump Announces Pick for Secretary of Health and Human Services

How to use Bluesky, the Twitter-like app that’s taking on Elon Musk’s X

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Recent posts

Two Magnificent Seven companies report this week. Only one will likely be among the biggest profit drivers.

Here’s how economic issues could help Republicans take back the U.S. Senate

Harris’s $25K for home buyers would lift prices, but her housing plan has advantages, economist says

After its August selloff, the U.S. dollar may face more downside risk ahead

Friday’s PCE inflation report: Here’s how financial markets may react

New-car sales expected to be up slightly in June, even as interest rates and prices remain high

PepsiCo probably raised its prices too much, and now it’ll have to pay, analyst says

Eli Lilly’s Zepbound pricing shuffle leaves some patients fearing higher costs

Cisco sees an AI boost, but this was the real star of the show

Worries about deficit spending after election bog down U.S. government debt

Lemonade’s stock slides 14% after digital insurer’s soft guidance offsets narrower-than-expected loss

Skechers shares rise on $1 billion buyback, more upbeat outlook

Eli Lilly’s Mounjaro cuts risk of developing Type 2 diabetes, study finds

Target’s stock rockets as store traffic grows, discretionary spending picks up

Nike sales fall as company prepares to bring in new CEO

Related articles

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Republicans clinch control of House, setting stage for quicker action on extending tax cuts

This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho

Cava is riding a strong wave, but the stock’s quadrupling in 2024 has analysts wary

Wells Fargo touches all-time high as analyst hikes price target to new level

Tesla is likely to thrive in a Trump administration. These are the ways these analysts see it happening.

Company

Follow us